Invacare, Healthdyne poised for proxy fight after Healthdyne's rejection of sweetened takeover bid.
This article was originally published in The Gray Sheet
Executive Summary
INVACARE, HEALTHDYNE TECHNOLOGIES POISED FOR PROXY BATTLE following Healthdyne's April 3 rejection of a sweetened $13.50-per-share takeover bid from Invacare. "Although we had hoped to avoid the expense of a proxy contest, that now appears unavoidable," Healthdyne Chairman Parker Petit says.